Drug Profile
BNC 210
Alternative Names: BNC-210; IW 2143Latest Information Update: 26 Mar 2024
Price :
$50
*
At a glance
- Originator Bionomics
- Developer Bionomics; EmpathBio
- Class Antidepressants; Anxiolytics; Behavioural disorder therapies; Small molecules
- Mechanism of Action Alpha7 nicotinic acetylcholine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Agitation; Anxiety disorders; Post-traumatic stress disorders
- No development reported Depressive disorders
Most Recent Events
- 21 Mar 2024 Bionomics plans to discuss the Phase IIb ATTUNE results with the US FDA in the second quarter of 2024
- 21 Mar 2024 Efficacy, adverse events, pharmacokinetics and pharmacodynamics data from phase IIb ATTUNE trial in Post-traumatic stress disorders released by Bionomics
- 21 Mar 2024 Bionomics plans to initiate a late-stage trial in post-traumatic stress disorder in the fourth quarter of 2024